We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

67 hedge funds and large institutions have $58M invested in Cascadian Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

208% more call options, than puts

Call options by funds: $2.36M | Put options by funds: $767K

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

6% more funds holding

Funds holding: 63 → 67 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less capital invested

Capital invested by funds: $62.8M → $58M (-$4.81M)

Holders
67
Holders Change
+4
Holders Change %
+6.35%
% of All Funds
1.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
22
Reduced
13
Closed
6
Calls
$2.36M
Puts
$767K
Net Calls
+$1.6M
Net Calls Change
-$1.57M

Top Buyers

Rank Fund Capital Flow
1
QF
QVT Financial
New York
+$3.43M
2
Franklin Resources
Franklin Resources
California
+$3.33M
3
ERSOT
Employees Retirement System of Texas
Texas
+$989K
4
BIT
BlackRock Institutional Trust
California
+$862K
5
First Eagle Investment Management
First Eagle Investment Management
New York
+$652K

Top Sellers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
-$2.62M
2
BFA
BlackRock Fund Advisors
California
-$1.29M
3
PC
PointState Capital
New York
-$1.03M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.03M
5
Goldman Sachs
Goldman Sachs
New York
-$436K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$195K +$42.8K +3,829 +26%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$173K -$306K -27,403 -63%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$142K – – –
VKH
29
Virtu KCG Holdings
New York
$134K +$74.7K +6,686 +110%
CS
30
Credit Suisse
Switzerland
$115K +$121K +10,854 New
ARTA
31
A.R.T. Advisors
New York
$111K – – –
WMSA
32
Weiss Multi-Strategy Advisers
New York
$104K – – –
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$84K – – –
Morgan Stanley
34
Morgan Stanley
New York
$80K -$117K -10,429 -58%
Tudor Investment Corp
35
Tudor Investment Corp
Connecticut
$70K +$74.3K +6,650 New
Citigroup
36
Citigroup
New York
$62K -$22.5K -2,017 -26%
DekaBank Deutsche Girozentrale
37
DekaBank Deutsche Girozentrale
Germany
$62K +$1.86K +166 +3%
GF
38
Gerstein Fisher
New York
$58K +$33.5K +3,000 +120%
HK
39
Horizon Kinetics
New York
$57K – – –
State Street
40
State Street
Massachusetts
$51K – – –
Dimensional Fund Advisors
41
Dimensional Fund Advisors
Texas
$50K – – –
LTFS
42
Ladenburg Thalmann Financial Services
Florida
$47K – – –
Charles Schwab
43
Charles Schwab
California
$46K – – –
LMF
44
LMR Master Fund
Cayman Islands
$44K +$46.8K +4,184 New
Citadel Advisors
45
Citadel Advisors
Florida
$39K -$219K -19,603 -84%
Goldman Sachs
46
Goldman Sachs
New York
$37K -$436K -38,979 -92%
U
47
UBS
Switzerland
$36K +$17.7K +1,583 +89%
FAAS
48
First Allied Advisory Services
California
$36K +$38.2K +3,417 New
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$35K +$37.3K +3,333 New
BA
50
BlackRock Advisors
Delaware
$27K +$8.91K +797 +44%
1
2
3

CASC Hedge Fund Activity: Q4 2013 in Review

67 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q4 2013, worth a combined $58M — down 7.7% from $62.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CASC positions and 6 closed out — a net gain of 4 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was QVT Financial, adding an estimated $3.43M. The largest seller was First Manhattan, cutting an estimated $2.62M.

  • 67 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q4 2013, up from 63 in Q3 2013.
  • Funds reported $58M of Cascadian Therapeutics, Inc. stock for Q4 2013, down 7.7% quarter-over-quarter.
  • 10 funds opened new Cascadian Therapeutics, Inc. positions in Q4 2013 and 6 closed out, a net change of +4 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q4 2013 was QVT Financial, an estimated $3.43M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q4 2013 was First Manhattan, an estimated $2.62M sold.

Based on aggregated 13F filings for Q4 2013.